C-terminal substitution of MDM2 interacting peptides modulates binding affinity by distinctive mechanisms.
Ontology highlight
ABSTRACT: The complex between the proteins MDM2 and p53 is a promising drug target for cancer therapy. The residues 19-26 of p53 have been biochemically and structurally demonstrated to be a most critical region to maintain the association of MDM2 and p53. Variation of the amino acid sequence in this range obviously alters the binding affinity. Surprisingly, suitable substitutions contiguous to this region of the p53 peptides can yield tightly binding peptides. The peptide variants may differ by a single residue that vary little in their structural conformations and yet are characterized by large differences in their binding affinities. In this study a systematic analysis into the role of single C-terminal mutations of a 12 residue fragment of the p53 transactivation domain (TD) and an equivalent ph
SUBMITTER: Brown CJ
PROVIDER: S-EPMC3164098 | biostudies-literature | 2011
REPOSITORIES: biostudies-literature
ACCESS DATA